ScreenPro FH - Screening project for familial hypercholesterolemia in central, Southern and Eastern Europe

Basic epidemiology

Richard Češka, Tomáš Freiberger, Andrey V. Susekov, György Paragh, Željko Reiner, Lale Tokgözoglu, Katarína Rašlová, Maciej Banach, Branislav Vohnout, Andrzej Rynkiewicz, Assen Goudev, Gheorghe Andrei Dan, Dan Gaita, Belma Pojskic, Ivan Pecin, Meral Kayikçioglu, Olena Mitchenko, Marat V. Ezhov, Gustavs Latkovskis, Žaneta Petrulioniene & 9 others Zlatko Fras, Nebojsa Tasic, Erkin M. Mirrakhimov, Tolkun Murataliev, Alexander B. Shek, Vladimír Tuka, Alexandros D. Tselepis, Elie M. Moubarak, Khalid Al Rasadi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: Despite great recent progress, familial hypercholesterolemia (FH) is still underestimated, under-diagnosed and thus undertreated worldwide. We have very little information on exact prevalence of patients with FH in the Central, Eastern and Southern Europe (CESE) region. The aim of the study was to describe the epidemiological situation in the CESE region from data available. Methods: All local leaders of the ScreenPro FH project were asked to provide local data on (a) expert guess of FH prevalence (b) the medical facilities focused on FH already in place (c) ScreenPro FH - projekt v oblasti screeningu zaměřený na familiární hypercholesterolemii ve střední, jižní a východní Evropě: základní epidemiologie diagnosis - epidemiology - familial hypercholesterolemia - screening the diagnostic criteria used (d) the number of patients already evidenced in local database and (e) the availability of therapeutic options (especially plasma apheresis). Results: With the guess prevalence of FH around 1:500, we estimate the overall population of 588 363 FH heterozygotes in the CESE region. Only 14 108 persons (2.4 %) were depicted in local databases; but the depiction rate varied between 0.1 % and 31.6 %. Only four out of 17 participating countries reported the the LDL apheresis availability. Conclusion: Our data point to the large population of heterozygous FH patients in the CESE region but low diagnostic rate. However structures through the ScreenPro FH project are being created and we can hope that the results will appear soon.

Original languageEnglish
Pages (from-to)25-30
Number of pages6
JournalVnitrni Lekarstvi
Volume63
Issue number1
Publication statusPublished - 2017

Fingerprint

Eastern Europe
Hyperlipoproteinemia Type II
Epidemiology
Blood Component Removal
Databases
Heterozygote
Population

Keywords

  • Diagnosis
  • Epidemiology
  • Familial hypercholesterolemia
  • Screening

ASJC Scopus subject areas

  • Internal Medicine
  • Medicine(all)
  • Cardiology and Cardiovascular Medicine

Cite this

Češka, R., Freiberger, T., Susekov, A. V., Paragh, G., Reiner, Ž., Tokgözoglu, L., ... Al Rasadi, K. (2017). ScreenPro FH - Screening project for familial hypercholesterolemia in central, Southern and Eastern Europe: Basic epidemiology. Vnitrni Lekarstvi, 63(1), 25-30.

ScreenPro FH - Screening project for familial hypercholesterolemia in central, Southern and Eastern Europe : Basic epidemiology. / Češka, Richard; Freiberger, Tomáš; Susekov, Andrey V.; Paragh, György; Reiner, Željko; Tokgözoglu, Lale; Rašlová, Katarína; Banach, Maciej; Vohnout, Branislav; Rynkiewicz, Andrzej; Goudev, Assen; Dan, Gheorghe Andrei; Gaita, Dan; Pojskic, Belma; Pecin, Ivan; Kayikçioglu, Meral; Mitchenko, Olena; Ezhov, Marat V.; Latkovskis, Gustavs; Petrulioniene, Žaneta; Fras, Zlatko; Tasic, Nebojsa; Mirrakhimov, Erkin M.; Murataliev, Tolkun; Shek, Alexander B.; Tuka, Vladimír; Tselepis, Alexandros D.; Moubarak, Elie M.; Al Rasadi, Khalid.

In: Vnitrni Lekarstvi, Vol. 63, No. 1, 2017, p. 25-30.

Research output: Contribution to journalArticle

Češka, R, Freiberger, T, Susekov, AV, Paragh, G, Reiner, Ž, Tokgözoglu, L, Rašlová, K, Banach, M, Vohnout, B, Rynkiewicz, A, Goudev, A, Dan, GA, Gaita, D, Pojskic, B, Pecin, I, Kayikçioglu, M, Mitchenko, O, Ezhov, MV, Latkovskis, G, Petrulioniene, Ž, Fras, Z, Tasic, N, Mirrakhimov, EM, Murataliev, T, Shek, AB, Tuka, V, Tselepis, AD, Moubarak, EM & Al Rasadi, K 2017, 'ScreenPro FH - Screening project for familial hypercholesterolemia in central, Southern and Eastern Europe: Basic epidemiology', Vnitrni Lekarstvi, vol. 63, no. 1, pp. 25-30.
Češka R, Freiberger T, Susekov AV, Paragh G, Reiner Ž, Tokgözoglu L et al. ScreenPro FH - Screening project for familial hypercholesterolemia in central, Southern and Eastern Europe: Basic epidemiology. Vnitrni Lekarstvi. 2017;63(1):25-30.
Češka, Richard ; Freiberger, Tomáš ; Susekov, Andrey V. ; Paragh, György ; Reiner, Željko ; Tokgözoglu, Lale ; Rašlová, Katarína ; Banach, Maciej ; Vohnout, Branislav ; Rynkiewicz, Andrzej ; Goudev, Assen ; Dan, Gheorghe Andrei ; Gaita, Dan ; Pojskic, Belma ; Pecin, Ivan ; Kayikçioglu, Meral ; Mitchenko, Olena ; Ezhov, Marat V. ; Latkovskis, Gustavs ; Petrulioniene, Žaneta ; Fras, Zlatko ; Tasic, Nebojsa ; Mirrakhimov, Erkin M. ; Murataliev, Tolkun ; Shek, Alexander B. ; Tuka, Vladimír ; Tselepis, Alexandros D. ; Moubarak, Elie M. ; Al Rasadi, Khalid. / ScreenPro FH - Screening project for familial hypercholesterolemia in central, Southern and Eastern Europe : Basic epidemiology. In: Vnitrni Lekarstvi. 2017 ; Vol. 63, No. 1. pp. 25-30.
@article{33c5a3a71a49494f8f201feb2535cf42,
title = "ScreenPro FH - Screening project for familial hypercholesterolemia in central, Southern and Eastern Europe: Basic epidemiology",
abstract = "Introduction: Despite great recent progress, familial hypercholesterolemia (FH) is still underestimated, under-diagnosed and thus undertreated worldwide. We have very little information on exact prevalence of patients with FH in the Central, Eastern and Southern Europe (CESE) region. The aim of the study was to describe the epidemiological situation in the CESE region from data available. Methods: All local leaders of the ScreenPro FH project were asked to provide local data on (a) expert guess of FH prevalence (b) the medical facilities focused on FH already in place (c) ScreenPro FH - projekt v oblasti screeningu zaměřen{\'y} na famili{\'a}rn{\'i} hypercholesterolemii ve středn{\'i}, jižn{\'i} a v{\'y}chodn{\'i} Evropě: z{\'a}kladn{\'i} epidemiologie diagnosis - epidemiology - familial hypercholesterolemia - screening the diagnostic criteria used (d) the number of patients already evidenced in local database and (e) the availability of therapeutic options (especially plasma apheresis). Results: With the guess prevalence of FH around 1:500, we estimate the overall population of 588 363 FH heterozygotes in the CESE region. Only 14 108 persons (2.4 {\%}) were depicted in local databases; but the depiction rate varied between 0.1 {\%} and 31.6 {\%}. Only four out of 17 participating countries reported the the LDL apheresis availability. Conclusion: Our data point to the large population of heterozygous FH patients in the CESE region but low diagnostic rate. However structures through the ScreenPro FH project are being created and we can hope that the results will appear soon.",
keywords = "Diagnosis, Epidemiology, Familial hypercholesterolemia, Screening",
author = "Richard Češka and Tom{\'a}š Freiberger and Susekov, {Andrey V.} and Gy{\"o}rgy Paragh and Željko Reiner and Lale Tokg{\"o}zoglu and Katar{\'i}na Rašlov{\'a} and Maciej Banach and Branislav Vohnout and Andrzej Rynkiewicz and Assen Goudev and Dan, {Gheorghe Andrei} and Dan Gaita and Belma Pojskic and Ivan Pecin and Meral Kayik{\cc}ioglu and Olena Mitchenko and Ezhov, {Marat V.} and Gustavs Latkovskis and Žaneta Petrulioniene and Zlatko Fras and Nebojsa Tasic and Mirrakhimov, {Erkin M.} and Tolkun Murataliev and Shek, {Alexander B.} and Vladim{\'i}r Tuka and Tselepis, {Alexandros D.} and Moubarak, {Elie M.} and {Al Rasadi}, Khalid",
year = "2017",
language = "English",
volume = "63",
pages = "25--30",
journal = "Vnitrni Lekarstvi",
issn = "0042-773X",
publisher = "Czech Medical Association J.E. Purkyne",
number = "1",

}

TY - JOUR

T1 - ScreenPro FH - Screening project for familial hypercholesterolemia in central, Southern and Eastern Europe

T2 - Basic epidemiology

AU - Češka, Richard

AU - Freiberger, Tomáš

AU - Susekov, Andrey V.

AU - Paragh, György

AU - Reiner, Željko

AU - Tokgözoglu, Lale

AU - Rašlová, Katarína

AU - Banach, Maciej

AU - Vohnout, Branislav

AU - Rynkiewicz, Andrzej

AU - Goudev, Assen

AU - Dan, Gheorghe Andrei

AU - Gaita, Dan

AU - Pojskic, Belma

AU - Pecin, Ivan

AU - Kayikçioglu, Meral

AU - Mitchenko, Olena

AU - Ezhov, Marat V.

AU - Latkovskis, Gustavs

AU - Petrulioniene, Žaneta

AU - Fras, Zlatko

AU - Tasic, Nebojsa

AU - Mirrakhimov, Erkin M.

AU - Murataliev, Tolkun

AU - Shek, Alexander B.

AU - Tuka, Vladimír

AU - Tselepis, Alexandros D.

AU - Moubarak, Elie M.

AU - Al Rasadi, Khalid

PY - 2017

Y1 - 2017

N2 - Introduction: Despite great recent progress, familial hypercholesterolemia (FH) is still underestimated, under-diagnosed and thus undertreated worldwide. We have very little information on exact prevalence of patients with FH in the Central, Eastern and Southern Europe (CESE) region. The aim of the study was to describe the epidemiological situation in the CESE region from data available. Methods: All local leaders of the ScreenPro FH project were asked to provide local data on (a) expert guess of FH prevalence (b) the medical facilities focused on FH already in place (c) ScreenPro FH - projekt v oblasti screeningu zaměřený na familiární hypercholesterolemii ve střední, jižní a východní Evropě: základní epidemiologie diagnosis - epidemiology - familial hypercholesterolemia - screening the diagnostic criteria used (d) the number of patients already evidenced in local database and (e) the availability of therapeutic options (especially plasma apheresis). Results: With the guess prevalence of FH around 1:500, we estimate the overall population of 588 363 FH heterozygotes in the CESE region. Only 14 108 persons (2.4 %) were depicted in local databases; but the depiction rate varied between 0.1 % and 31.6 %. Only four out of 17 participating countries reported the the LDL apheresis availability. Conclusion: Our data point to the large population of heterozygous FH patients in the CESE region but low diagnostic rate. However structures through the ScreenPro FH project are being created and we can hope that the results will appear soon.

AB - Introduction: Despite great recent progress, familial hypercholesterolemia (FH) is still underestimated, under-diagnosed and thus undertreated worldwide. We have very little information on exact prevalence of patients with FH in the Central, Eastern and Southern Europe (CESE) region. The aim of the study was to describe the epidemiological situation in the CESE region from data available. Methods: All local leaders of the ScreenPro FH project were asked to provide local data on (a) expert guess of FH prevalence (b) the medical facilities focused on FH already in place (c) ScreenPro FH - projekt v oblasti screeningu zaměřený na familiární hypercholesterolemii ve střední, jižní a východní Evropě: základní epidemiologie diagnosis - epidemiology - familial hypercholesterolemia - screening the diagnostic criteria used (d) the number of patients already evidenced in local database and (e) the availability of therapeutic options (especially plasma apheresis). Results: With the guess prevalence of FH around 1:500, we estimate the overall population of 588 363 FH heterozygotes in the CESE region. Only 14 108 persons (2.4 %) were depicted in local databases; but the depiction rate varied between 0.1 % and 31.6 %. Only four out of 17 participating countries reported the the LDL apheresis availability. Conclusion: Our data point to the large population of heterozygous FH patients in the CESE region but low diagnostic rate. However structures through the ScreenPro FH project are being created and we can hope that the results will appear soon.

KW - Diagnosis

KW - Epidemiology

KW - Familial hypercholesterolemia

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=85014017730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014017730&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 25

EP - 30

JO - Vnitrni Lekarstvi

JF - Vnitrni Lekarstvi

SN - 0042-773X

IS - 1

ER -